Hoth Expands HT-001 Trial as Patient Demand Surges
Event summary
- Hoth Therapeutics adds Regis Clinical Research as a new site for its CLEER-001 Phase 2a trial, expanding patient access in South Florida.
- Interim data shows 100% of open-label cohort patients achieved primary efficacy endpoint by week six.
- Over 65% of patients reported meaningful reductions in pain and itching with zero dose-limiting toxicities observed.
- Case study at AAD Annual Meeting demonstrated complete lesion resolution in a metastatic breast cancer patient after one week of HT-001 use.
The big picture
Hoth's expansion reflects growing physician and patient interest in HT-001, a potential first-in-class treatment for severe skin toxicities associated with EGFR inhibitor cancer therapies. With no current FDA-approved options for these debilitating side effects, positive interim results position HT-001 as a potential paradigm shift in oncology supportive care. The addition of Regis Clinical Research demonstrates Hoth's ability to scale its trial infrastructure in response to unmet medical need.
What we're watching
- Trial Momentum
- Whether Hoth can sustain this accelerated enrollment pace across additional sites.
- Regulatory Pathway
- How the compelling interim data will factor into potential FDA discussions.
- Market Opportunity
- The pace at which HT-001 could capture share in the $200,000-patient annual EGFR inhibitor market.
Related topics